Drug addiction. Part III. Pharmacotherapy of addiction

Polish Journal of Pharmacology

Volumn 53, Issue 5, 2001, Pages 415-434

  Vetulani, J ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Addiction pharmacotherapy; Addictive stimulants; Antiaddiction vaccines; General antiaddictive strategies; Legal psychotrophic substances; Specific antiaddictive strategies

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 2 AMINO 4,5 (1,2 CYCLOHEXYL) 7 PHOSPHONOHEPTANOIC ACID; 4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; ACAMPROSATE; AMFEBUTAMONE; ANTIBODY; BACLOFEN; BP 897; BUPRENORPHINE; BUPROPION SR; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CATALYTIC ANTIBODY; CHOLINESTERASE; DIZOCILPINE; ENZYME; IBOGAINE; LEVACETYLMETHADOL; MEMANTINE; METHADONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALTREXONE; NIFEDIPINE; NIMODIPINE; NORTRIPTYLINE; PHENCYCLIDINE; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG; VACCINE; VANOXERINE; VIGABATRIN;

ADAPTATION; ALCOHOLISM; BLOOD BRAIN BARRIER; BRAIN FUNCTION; CALCIUM TRANSPORT; CENTRAL NERVOUS SYSTEM; COMPLEX FORMATION; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DRUG DEPENDENCE; DRUG MECHANISM; EXCITABILITY; GABAERGIC SYSTEM; HEROIN DEPENDENCE; HUMAN; MAINTENANCE THERAPY; MOUSE; NONHUMAN; PATHOGENESIS; RAT; RELAPSE; REVIEW; REWARD; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

4-AMINOBUTYRATE TRANSAMINASE; ANIMALS; BRAIN; CALCIUM CHANNEL BLOCKERS; DOPAMINE UPTAKE INHIBITORS; HUMANS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, N-METHYL-D-ASPARTATE; SUBSTANCE-RELATED DISORDERS;

EID: 0035207520     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (155)

1. Ability of baclofen in reducing alcohol craving and intake: II-Preliminary clinical evidence
2. Combining ondansetron and naltrexone treats biological alcoholics: Corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker
3. Design and synthesis of a morphine-6-succinyl-bovine serum albumin hapten for vaccine development
4. Cortical dihydropyridine binding sites and behavioral syndrome in morphine abstinent rat
5. Reduction of morphine dependence and potentiation of analgesia by chronic co-administration of nifedipine
6. Natural and artificial enzymes against cocaine. I. Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats
7. Comparison of methadone and high dosage buprenorphine users in French care centres
8. In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats
9. The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered
10. Effects of NMDA receptor channel blockers, dizocilpine and memantine, on the development of opiate analgesic tolerance induced by repeated morphine exposures or social defeats in mice
11. Antidepressants in smoking cessation: Is effectiveness independent of the antidepressant effect?
12. Effects of NMDA receptor antagonists on cocaine-conditioned motor activity in rats
13. Effects of N-methyl-D-aspartate receptor antagonists on reinstatement of cocaine-seeking behavior by priming injections of cocaine or exposures to cocaine-associated cues in rats
14. Effects of calcium channel antagonists on the reinforcing properties of morphine, ethanol and cocaine as measured by place conditioning
15. Alcohol craving and heavy drinking relapses - Advances in experimental psychopharmacotherapy (Polish)
16. Changes in heroin self-administration by a rhesus monkey after morphine immunisation
17. Attenuation of cocaine-induced locomotor activity by butyrylcholinesterase
18. A second-generation vaccine protects against the psychoactive effects of cocaine
19. Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR12909)
20. Dopamine receptor partial agonists could address the duality of cocaine craving
21. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine
22. The effects of memantine on the subjective, reinforcing and cardiovascular effects of cocaine in humans
23. Major depression following smoking cessation
24. Review of naltrexone, a long-acting opiate antagonist
25. Isradipine combined with naltrexone persistently reduces the reward-relevant effects of cocaine and alcohol
26. Long-term D1 dopamine receptor sensitization in neonatal 5-OH-DA lesioned rats is blocked by an NMDA antagonist
27. Glycine and N-methyl-D-aspartate receptors: Physiological significance and possible therapeutic applications
28. A pharmacologic strategy for the treatment of nicotine addiction
29. A novel strategy for the treatment of cocaine addiction
30. A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use
31. Analgesic effects of amlodipine and its interaction with morphine and ketorolac-induced analgesia
32. Medical treatment for diacetyl-morphine (heroin) addiction
33. The development of behavioral sensitization to apomorphine is blocked by MK-801
34. Editorial: Visual field constriction on vigabatrin
35. Cocaine cross-sensitization to dopamine uptake inhibitors: Unique effects of GBR12909
36. Staff beliefs about addiction treatment
37. Development of a therapeutic vaccine for the treatment of cocaine addiction
38. Efficacy of a therapeutic cocaine vaccine in rodent models
39. Naltrexone: A controversial therapy for alcohol dependence
40. Alcoholism treatment in the United States. An overview
41. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: A preliminary trial
42. Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine
43. The role of the National Institute on Drug Abuse in the development of naltrexone
44. Efficacy and tolerability of bupropion sustained-release for smoking cessation: A review of pivotal studies
45. Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs
46. The influence of three L-type calcium channel blockers on morphine effects in healthy volunteers
47. Pharmacotherapy of nicotine dependence
48. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism
49. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial
50. Nimodipine improves information processing in substance abusers
51. Endogenous opioid systems and alcohol addiction
52. Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats
53. Dopamine neurons report an error in the temporal prediction of reward during learning
54. Bupropion: A review of its use in the management of smoking cessation
55. A comparison of sustained-release bupropion and placebo for smoking cessation
56. Site-specific NMDA receptor antagonists produce differential effects on cocaine self-administration in rats
57. Human pharmacology and abuse potential of the analgesic buprenorphine: A potential agent for treating narcotic addiction
58. MK-801 prevents the development of behavioral sensitization during repeated morphine administration
59. Blockade of 'reverse tolerance' to cocaine and amphetamine by MK-801
60. Deaths involving buprenorphine: A compendium of French cases
61. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine
62. Effect of isradipine, a dihydropyridine-calcium antagonist on i.v. self-administration of morphine in rats
63. Analgesic and reinforcing effects of morphine in mice. Influence of Bay K-8644 and nimodipine
64. Modulation of cocaine intravenous self-administration in drug-naive animals by dihydropyridine Ca2+ channel modulators
65. Calcium antagonists isradipine and nimodipine suppress cocaine and morphine intravenous self-administration in drug-naive mice
66. Ibogaine alters synaptosomal and glial glutamate release and uptake
67. Acamprosate appears to decrease alcohol intake in weaned alcoholics
68. Bupropion treatment of depression to assist smoking cessation
69. Baclofen as a cocaine anti-craving medication: A preliminary clinical study
70. Ibogaine in the treatment of chemical depencency disorders: Clinical perspectives
71. Alcohol input and creative output
72. Creative achievement and psychopathology: Comparison comparison among professions
73. Mental illness and creative activity in female writers
74. Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl-D-aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro
75. Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa
76. A detailed longitudinal analysis on the use of naltrexone in the treatment of bulimia
77. Ketamine, PCP, and alcohol trigger widespread cell death in the brains of developing rats
78. Antibody may treat PCP overdose and abuse, also block prenatal harm
79. Butyrylcholinesterase: An enzyme antidote for cocaine intoxication
80. Buprenorphine suppresses heroin use by heroin addicts
81. Buprenorphine suppresses cocaine self-administration by rhesus monkeys
82. Clinical and histopathological description of a new case of vigabatrin-induced gingival overgrowth
83. A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats
84. Effects of various Ca2+ channel antagonists on morphine analgesia, tolerance and dependence, and on blood pressure in the rat
85. Effects of nifedipine pretreatment on subjective and cardiovascular responses to intravenous cocaine in humans
86. The use of bupropion hydrochloride for smoking cessation therapy
87. Naltrexone in the treatment of alcoholism: A clinical review
88. Ibogaine induces glial activation in parasagittal zones of the cerebellum
89. Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline
90. Opioid antagonists in the treatment of alcohol dependence: Clinical efficacy and prevention of relapse
91. Competitive and noncompetitive NMDA antagonists block sensitization to methamphetamine
92. Pharmacotherapy of smoking cessation
93. The effects of naltrexone on alcohol and cocaine use in dually addicted patients
94. Modulation of phencyclidine (PCP) pharmacokinetics with PCP-specific Fab fragments
95. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - A review of preclinical data
96. Enhancement of the epidural morphine-induced analgesia by systemic nifedipine
97. Ethanol-reinforced behaviour in the rat: Effects of uncompetitive NMDA receptor antagonist, memantine
98. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist
99. Addiction suppression by NMDA receptor antagonists: History of discovery and mechanism of action of ibogaine (Polish)
100. Mesolimbic NMDA receptors are implicated in the expression of conditioned morphine reward
101. Clinically available NMDA antagonist, memantine, attenuates tolerance to analgesic effects of morphine in a mouse tail flick test
102. Clinically available NMDA receptor antagonists memantine and dextromethorphan reverse existing tolerance to the antinociceptive effects of morphine in mice
103. 100 years of ibogaine: Neurochemical and pharmacological actions of a putative anti-addictive drug
104. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence
105. BP-897 Bioprojet
106. Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats
107. L-NAME and MK-801 attenuate sensitization to the locomotor-stimulating effect of cocaine
108. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801
109. Is the short-latency dopamine response too short to signal reward error?
110. Baclofen attenuates the reinforcing effects of cocaine in rats
111. GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine
112. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909
113. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence
114. Tight binding dopamine reuptake inhibitors as cocaine antagonists. A strategy for drug development
115. Naltrexone versus acamprosate: One year follow-up of alcohol dependence treatment
116. Évaluation des traitements médicamenteux de l'alcoolodépendance psychique primaire
117. Nimodipine-enhanced opiate analgesia in cancer patients requiring morphine dose escalation: A double-blind, placebo-controlled study
118. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence
119. Naloxone reduces the neurochemical and behavioral effects of amphetamine but not those of cocaine
120. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse
121. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: A randomized controlled trial
122. Low-affinity NMDA receptor channel blockers inhibit acquisition of intravenous morphine self-administration in naive mice
123. Ethanol drug discrimination in rats: Substitution with GABA agonists and NMDA antagonists
124. The calcium channel antagonist nifedipine causes confusion when used to treat opiate withdrawal in morphine-dependent patients
125. Anti-craving compounds for ethanol: New pharmacological tools to study addictive processes
126. Peripheral cocaine-blocking agents: New medications for cocaine dependence
127. Comparison of buprenorphine and methadone in the treatment of opioid dependence
128. Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption
129. Effects of intrathecal injection of nimodipine, omega-conotoxin GVIA, calmidazolium, and KN-62 on the antinociception induced by cold water swimming stress in the mouse
130. Iboga compounds reverse the behavioural disinhibiting and corticosterone effects of acute methamphetamine: Implications for their antiaddictive properties
131. Excitatory amino acids and drugs of abuse: A role for N-methyl-D-aspartate receptors in drug tolerance, sensitization and physical dependence
132. Dose-response and duration effects of acute administrations of cocaine and GBR12909 on dopamine synthesis and transporter in the conscious monkey brain: PET studies combined with microdialysis
133. Effects of the non-competitive NMDA-receptor antagonist memantine on morphine- and cocaine-induced potentiation of lateral hypothalamic brain stimulation reward
134. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats
135. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats
136. Limited role of naltrexone in the treatment of opiate addiction
137. Calcium and voltage-dependent calcium channels (Polish)
138. Drug addiction. Psychoactive substances in the past and presence
139. Drug addiction. Neurobiology of addiction. Review
140. Doses of GBR-12909 that suppress cocaine self-administration in non-human primates substantially occupy dopamine transporters as measured by [11C] WIN35,428 PET scans
141. 11C]raclopride continuous infusion PET scans
142. Newer antiepileptic drugs: Advantages and disadvantages
143. Intravenous and oral 1-alpha-acetylmethadol: Pharmacodynamics and pharmacokinetics in humans
144. Signs and symptoms during the acute phase of smoking cessation
145. The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors
146. Without crash, without rush (Polish)
147. Coadministration of MK-801 with amphetamine, cocaine or morphine prevents rather than transiently masks the development of behavioral sensitization
148. Repeated administration of MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamine
149. Randomized trial of naltrexone for smoking cessation
150. Smoking cessation. Pharmacologic approaches
151. An improved cocaine hydrolase: The A328Y mutant of human butyrylcholinesterase is 4-fold more efficient
152. A comparative study with oral nifedipine, intravenous nimodipine, and magnesium sulfate in postoperative analgesia
153. Blood-borne medications could intercept drugs before they reach the brain